A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder.
10.9758/cpn.2017.15.4.328
- Author:
Sevcan Karakoç DEMIRKAYA
1
;
Hatice AKSU
;
Börte Gürbüz ÖZGÜR
Author Information
1. Department of Child and Adolescent Psychiatry, Adnan Menderes University Faculty of Medicine, Aydın, Turkey. Sevcan.karakoc@adu.edu.tr
- Publication Type:Original Article
- Keywords:
Antipsychotic agents;
Risperidone;
Conduct disorder
- MeSH:
Adolescent*;
Aggression;
Antipsychotic Agents;
Appetite;
Attention Deficit Disorder with Hyperactivity;
Child;
Compliance;
Conduct Disorder*;
Depression;
Female;
Humans;
Informed Consent;
Leg;
Medical Records;
Muscle Cramp;
Parents;
Retrospective Studies*;
Risperidone*;
Substance-Related Disorders;
Weight Gain;
Weights and Measures
- From:Clinical Psychopharmacology and Neuroscience
2017;15(4):328-336
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Risperidone has been widely used to control aggression and conduct disorder (CD) in youth; however, treatment compliance is a major problem in CD. Our aim is to evaluate the effectiveness and tolerability of long-acting risperidone (LAR) in treating nonadherent cases. METHODS: The medical records of children and adolescents who had CD and were nonadherent to conventional drugs and psychosocial interventions (and therefore taking LAR) were reviewed. Informed consent on offlabel use of LAR was obtained from the parents. Clinical Global Impression (CGI) Severity (CGI-S) and CGI-Improvement scales were used and baseline and end points were compared. RESULTS: The study comprised 14 children and adolescents (5 girls, 9 boys). All had comorbid disorders: substance use disorder (n=8), attention deficit hyperactivity disorder (n=6), and major depression (n=2). Mean duration of LAR use was 3.1 months (1.5–8 months). We observed significant improvements in the baseline and endpoint CGI-S scores for CD in all but one patient (Z=−3.198; p < 0.001). Only mild adverse effects were observed: weight gain (n=2), sedation (n=1), leg cramps (n=1), and increased appetite with no weight gain (n=1). CONCLUSION: LAR is effective and tolerable for patients with CD who can’t be medicated with oral preparations due to non-adherence to treatment. Even short-term LAR use is effective to get compliance. As CD predicts numerous problems in adulthood, appropriate treatment is crucial. To our knowledge, this is the first study on LAR use in youth with CD. The use of LAR deserves careful consideration and further controlled studies are needed to confirm our findings.
